Exelixis

NASDAQ: EXEL
$17.77
+$0.35 (+2.0%)
Closing price January 28, 2022
The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
Exelixis saw its shares make a handy gain on Wednesday after the company received the nod from the FDA for Cabometyx tablets.
With tax reform having cleared the Senate and going back to the House, investors were looking for a higher stock market open on Wednesday.
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
Some of the top biotech stocks could become extremely volatile before and after earnings. These four that may be worth a look for aggressive investors.
Tuesday’s top analyst upgrades, downgrades and initiations include Apple, CVS Health, Priceline, Teva Pharmaceutical and Workday.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Shares of Exelixis saw a handy gain early Monday morning after the company reported positive results from its mid-stage trial for the treatment of renal cell carcinoma.
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
As the markets continue to stumble through May, and the volatility appears to be creeping up some, the end of the first-quarter earnings parade has opened the door for insiders to buy shares.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic...